Turkish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
proteinase/kanser
Bağlantı panoya kaydedilir
Sayfa 1 itibaren 29 Sonuçlar
Proteinases destroy cancer tumor's solid structure and kill cancer cells locally
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
REFERENCE TO SEQUENCE LISTINGS, A TABLE, OR A COMPUTER PROGRAM LISTING COMPACT DISC APPENDIX
Not Applicable
BACKGROUND OF THE INVENTION
Cancers are collectively a very large group of devastating diseases characterized by uncontrolled cell division, growth, invasiveness and the capability of
Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
This invention was not sponsored by any federal research or development fund.
BACKGROUND OF THE INVENTION
The idea of using proteinases to do solid-tumor microsurgery has led to the discovery of a new class of drugs that can eliminate
Nucleic acids encoding chimeric proteins comprising BMP-2 and a proteinase inhibitor
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a 35 U.S.C. .sctn.371 National Phase Entry Application from PCT/DE01/01510, filed Apr. 18, 2001 and designating the United States. This application further claims foreign priority to German application DE 100 20 125.3, filed Apr. 18,
Inhibition of cancer procoagulant
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
This invention relates to selective peptidyl inhibitors of cancer procoagulant (CP), a protein elaborated by malignant, but not normal, animal and human cells, and to the use of these selective peptidyl inhibitors in cancer therapy and in CP removal from blood.
BACKGROUND OF
3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,
4-substitued-3-[1 or 2 amino acid residue]-azetidin-2-one derivatives useful as cysteine proteinase inhibitor
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF INVENTION
Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986, 122,
4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,
4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,
Prostate specific antigen (PSA)-proteinase inhibitor complexes
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
The prostate specific antigen (PSA) was first purified from prostatic tissue (Wang et al. Invest Urol 1979), but the same protein was almost simultaneously and independently characterized in the seminal plasma (Hara et al. J Lab Clin Med 1989; Graves et al. N Engl J Med
DNA molecules encoding human HELA2 or testisin serine proteinases
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
The present invention related generally to novel molecules and more particularly novel proteinaceous molecules involved in or associated with regulation of cell activities and/or viability. The present invention is particularly directed to novel serene proteinases and a novel
CST1, DCC1, IFITM1 or MELK as markers for diagnosing stomach cancer
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
STATEMENT REGARDING SEQUENCE LISTING
The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is
Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
The invention relates to an enzyme, arginine deiminase. In particular, it relates to a unique arginine deiminase isolated from mycoplasmas. More particularly, the invention is directed to a mycoplasmal proteinase K resistant arginine deiminase and to a method of preparing
Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND TO THE INVENTION
Proteinases form a substantial group of biological molecules which to date constitute approximately 2% of all the gene products identified following analysis of several completed genome sequencing programmes. Proteinases have evolved to participate in an enormous range of
Therapeutic use for ALPHA1 proteinase inhibitor in hematopoiesis
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 15, 2012, is named 86519CON.txt and is 11,216 bytes in size.
BACKGROUND OF THE
Therapeutic use for .alpha..sub.1 proteinase inhibitor in hematopoiesis
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
Full length active .alpha..sub.1 proteinase inhibitor (.alpha..sub.1PI, .alpha..sub.1 antitripsin) is composed of 394 amino acids (aa) having a mass of approximately 55 kDa when fully glycosylated (Berninger, 1985). Hepatocytes are the primary source of .alpha..sub.1PI,
Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı
- 55 dilde çalışır
- Bilim destekli bitkisel kürler
- Görüntüye göre bitki tanıma
- Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
- Aramanızla ilgili bilimsel yayınları okuyun
- Şifalı bitkileri etkilerine göre arayın
- İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın
Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır
